MENU
+Compare
ATXS
Stock ticker: NASDAQ
AS OF
May 14, 04:59 PM (EDT)
Price
$3.97
Change
+$0.07 (+1.79%)
Capitalization
220.09M

ATXS Astria Therapeutics Forecast, Technical & Fundamental Analysis

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases... Show more

Industry: #Biotechnology
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ATXS with price predictions
May 13, 2025

Aroon Indicator for ATXS shows an upward move is likely

ATXS's Aroon Indicator triggered a bullish signal on May 13, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator showed a similar pattern. In of the 180 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATXS's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATXS advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ATXS as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ATXS turned negative on May 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ATXS broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.983) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.920).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ATXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ATXS is expected to report earnings to fall 16.55% to -48 cents per share on August 11

Astria Therapeutics ATXS Stock Earnings Reports
Q2'25
Est.
$-0.48
Q1'25
Missed
by $0.13
Q4'24
Beat
by $0.01
Q3'24
Est.
$-0.42
Q2'24
Missed
by $0.06
The last earnings report on May 13 showed earnings per share of -57 cents, missing the estimate of -44 cents. With 371.36K shares outstanding, the current market capitalization sits at 220.09M.
A.I. Advisor
published General Information

General Information

a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
75 State Street
Phone
+1 617 349-1971
Employees
59
Web
https://www.astriatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USWGX30.05N/A
N/A
Victory Sustainable World A
FSKLX12.25N/A
N/A
Fidelity SAI Intl Low Volatil Idx
LGCCX17.29N/A
N/A
Lord Abbett Global Equity C
FLAPX19.01N/A
N/A
Fidelity Flex Mid Cap Index
FSYNX9.54N/A
N/A
Fidelity Advisor Sustainable EM Eq M

ATXS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-10.76%
KYMR - ATXS
54%
Loosely correlated
-3.20%
TRDA - ATXS
53%
Loosely correlated
-1.36%
APGE - ATXS
51%
Loosely correlated
+0.40%
XENE - ATXS
50%
Loosely correlated
-17.43%
CRNX - ATXS
50%
Loosely correlated
-7.11%
More